1
Olaf Kinstler, Colin Gegg, Aimee Freeman, Thomas Boone: Chemically modified novel erythropoietin stimulating protein compositions and methods. Amgen, Craig A Crandall, Ron K Levy, Stuart L Watt, July 1, 2003: US06586398 (144 worldwide citation)

The present invention broadly relates to the field of protein modification, and, more specifically, the attachment of water soluble polymers to novel erythropoietin stimulating protein (NESP).


2
Lawrence M Blatt, Milton W Taylor: Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect. Amgen, Robert R Cook, Craig A Crandall, December 13, 1994: US05372808 (106 worldwide citation)

Methods for the treatment of cell proliferation disorders, viral infections, and other conditions without causing significant side effects normally associated with interferon therapy, involving administering to a patient in need thereof a therapeutically effective amount of consensus human leukocyte ...


3
Colin Gegg, Olaf Kinstler: Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility. Amgen, Craig A Crandall, Ron K Levy, Steven M Odre, July 16, 2002: US06420339 (94 worldwide citation)

The present invention relates generally to the chemical modification of biologically active agents. More, specifically, the invention relates to a novel approach to engineer, through mutagenesis and site-directed chemical conjugation, specific, well-defined dualPEGylated-protein bioconjugates, consi ...


4
Olaf B Kinstler, Nancy E Gabriel, Christine E Farrar, Randolph B DePrince: N-terminally chemically modified protein compositions and methods. Amgen, Craig A Crandall, Ron K Levy, Steven M Odre, November 16, 1999: US05985265 (88 worldwide citation)

Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel chemically modified G-CSF compositions and related methods of ...


5
Subodh Shah, Weiguo Dai: Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents. Amgen, Craig A Crandall, Ron K Levy, Stephen M Odre, September 17, 2002: US06451346 (84 worldwide citation)

The present invention relates generally to the development of pharmaceutical compositions which provide for sustained release of biologically active polypeptides. More specifically, the invention relates to the use of pH/thermosensitive biodegradable hydrogels, consisting of a A-B di block or A-B-A ...


6
Larry Blatt, Michael Klein: Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon. Amgen, Craig A Crandall, Ron K Levy, Steven M Odre, November 9, 1999: US05980884 (69 worldwide citation)

Methods for the retreatment, using a therapeutically effective amount of interferon consensus, of patients with HCV who exhibit serum ALT values above the upper limit of normal after previous treatment with interferon.


7
Subodh Shah: Thermosensitive biodegradable hydrogels for sustained delivery of leptin. Amgen, Craig A Crandall, Ron K Levy, Steve M Odre, April 1, 2003: US06541033 (45 worldwide citation)

The present invention relates generally to the development of pharmaceutical compositions which provide for sustained release of biologically active polypeptides. More specifically, the invention relates to the use of thermosensitive, biodegradable hydrogels, consisting of a block copolymer of poly( ...


8
David Collins, Younsik Cha, David Brems: Stable protein: phospholipid compositions and methods. Amgen, Craig A Crandall, Ron K Levy, Steven M Odre, February 23, 1999: US05874075 (41 worldwide citation)

The invention relates to stable compositions of proteins and related methods wherein a protein capable of transitioning into the molten globular state is contacted with a negatively charged lipid vesicle, thereby stabilizing the protein against thermally-induced aggregation, denaturation, and loss o ...


9
Tatsutoshi Nakahata: Use of stem cell factor and soluble interleukin-6 receptor for the ex vivo expansion of hematopoietic multipotential cells. Amgen, Tosoh Corporation, Craig A Crandall, Ron Levy, Steven M Odre, January 19, 1999: US05861315 (41 worldwide citation)

Stem cell factor in combination with soluble interleukin-6 receptor, interleukin-6, for gp130 signaling, supports the proliferation, differentiation and terminal maturation of blood cells from normal human hematopoietic multipotential cells.


10
Laszlo Takacs: Assays and devices for the detection of extrahepatic biliary atresia. Amgen, Craig A Crandall, Daniel R Curry, Steven M Odre, February 11, 1997: US05601986 (36 worldwide citation)

The present invention involves a variety of assay methods and devices for screening or diagnosing the occurrence of extrahepatic biliary atresia. In particular the methods and devices involve an antibody specifically for the detection of dipeptidyl peptidase IV in a test sample as indicative of extr ...